Michele V. McNeill, Pharm.D.
Joined the amfAR board in December 1996. Expertise in management of process for drug testing and
approval. Was instrumental in establishing the Paul Corser AIDS Research
Opportunity Fund, pledging two dollars for every dollar, up to $100,000, contributed by amfAR donors. Opportunity Fund supports projects that fall outside amfAR’s targeted research initiatives or
regular grant cycles.
Dr. McNeill is founder and former chief executive officer of Kern McNeill International (KMI), a contract research
organization providing clinical drug development services to research-based
pharmaceutical manufacturers. At KMI, she pioneered work to provide access to
investigational drugs for serious, life-threatening illnesses, such as AIDS and
cancer. More than 80,000 patients received treatment from programs managed by
KMI, prior to its acquisition several years ago by United Healthcare, Inc.
Earlier, Dr. McNeill practiced clinical pharmacy at Thomas Jefferson University
Hospital in Philadelphia and at Erie County Medical Center in Buffalo. She
launched her career in the pharmaceutical industry at Warner Lambert and went
on to hold key management positions at Hoffmann-La Roche and Ciba Geigy (now
Novartis). Currently, Dr. McNeill serves on the Therapeutic and Research Working
Group in the Office of AIDS Research at the National Institutes of Health.
She and her husband, Doug, live in Longboat Key, FL.